Brainwave Discovery is dedicated to the discovery and development of new drugs to combat Alzheimer's Disease. To find out more about our technology and partnering opportunities please email us.

info@brainwave-discovery.com

ABOUT US

BWD is now increasingly focussed on using its high throughput drug screening technology to discover compounds that are potential treatments for Alzheimer's disease.

BWD is based on science from the University of Edinburgh and University of Glasgow. BWD has been trading since 2010 as a contract research organisation and was identified by Scottish Enterprise as a company with significant growth potential.

SENIOR MANAGEMENT

Dr. R. Wayne Davies: Chief Executive Officer

Wayne has a unique combination of international level scientific achievement with extensive business experience. He has been CEO, a senior manager or a Director for six biotechnology companies in Canada, the UK, Sweden and the USA. Wayne is also an expert in genetics, molecular biology and neuroscience, with many publications in major scientific journals, and is an elected member of EMBO for work on RNA catalysis and the mitochondrial genome. He was Professor of Biotechnology at the University of Glasgow for many years, where he focused on applied neuroscience, and is now an Honorary Professor in the School of Informatics at the University of Edinburgh. He brings mammalian molecular neuroscience expertise and relevant commercial experience to the company.

Professor J. Douglas Armstrong: Chief Scientific and Operating Officer

Douglas is the Professor of Systems Neurobiology at the University of Edinburgh and Assistant Professor (Adjunct) of Biochemistry and Cell Biology at Rice University. He is an expert in bioinformatics, computing, systems biology, genetics and molecular biology. His experimental work has made extensive use of the Drosophila system, and a major focus is the systems biology of the synapse and its perturbation in disease. This encompasses direct investigation of protein complexes, computer simulations of these complexes and modeling of information flow through them. He provides core bioinformatics, synthetic biology, Drosophila neurogenetics and behaviour expertise to the company.

Matt B Mahoney: Director of Business Development - North American Region

Matt B. Mahoney, Director of Business Development - North American Region. After studying genetics at the University of California, Berkeley, Matt joined the Alzheimer's disease team at Exelixis Inc., from where he was recruited to EnVivo Pharmaceuticals. He helped to optimize and run their Drosophila behavioral screening platform and was integral to the identification of multiple treatment candidates for neurodegenerative diseases. This group spun off into a separate company, Vitruvean, LLC, where Matt was responsible for Drosophila-based drug screening, marketing and business development. This invaluable experience is now focused on the development of Brainwave Discovery's business in the USA and Canada. Customers in this region should contact Matt directly on m.mahoney@brainwave-discovery.com

Dr. Joanna Young: Director of Business Development - Europe Region

Joanna Young, Director of Business Development - Europe Region. Joanna worked with Drosophila for ten years before going into business. After completing her BSc at the University of Edinburgh, she stayed at the university to study for an MSc and PhD in informatics and neuroscience, followed by three years postdoctoral work in neuroscience and behaviour. As an entrepreneur she has established her own company in the science communication field, and is also entrepreneurship club coordinator at the University of Edinburgh Business School. Her combination of science and business experience is ideal for the development of Brainwave Discovery's business in Europe. Customers in this region should contact Joanna directly at j.young@brainwave-discovery.com

Dr. Manuela Marescotti: Research & Development Manager

Manuela is a neuroscientist specialising in neurodegeneration in Drosophila melanogaster. Early on in her career, she developed an interest in genetics that led her to study for a BSc in Biotechnology of Healthcare and, subsequently, for an MSc in Medical Biotechnology at the University of Naples "Federico II". After her MSc, Manuela obtained a PhD in neuroscience at the University of Edinburgh. She is an expert in molecular biology, Drosophila genetics, biochemistry and cell biology.